#GeneTherapy #Manufacturing at #ArkTherapeutics

Ark Therapeutics and PsiOxus Therapeutics Ltd have announced that their partnership has successfully achieved its first milestone, by the timely manufacture of PsiOxus’s ColoAd1 oncoloytic adenoviral product. The material was manufactured at Ark’s facility in Kuopio, Finland, using Ark’s proprietary suspension based single use process (“ATOSUS”), which was able to achieve the required product quality and demonstrate capability to exceed …